Development and Commercialization of Biosimilars in India - The author aims to present the current status of India in this context, the challenges that need to be overcome, and some recommendations th

ADVERTISEMENT

Development and Commercialization of Biosimilars in India
The author aims to present the current status of India in this context, the challenges that need to be overcome, and some recommendations that may alleviate these challenges.


BioPharm International
Volume 24, Issue 11, pp. 36-40

REFERENCES

1. G. Walsh, Nature Biotechnol. 28 (9) 917–924 (2010).

2. J. Hodgson, Nature Biotechnol. 27 (11) 963–965 (2009).

3. P. Narang, Datamonior Biosimilar Series 2008 (Datamonitor, London. June 2009).

4. C. Chakraborty and G. Agoramoorthy, Biotechnology Advances 28 (1) 1–6 (2010).

5. S. Chaturvedi, The Indian Jrnl. of Labour Econ. 52 (2) 693–712 (2009).

6. S. Natesh and M. Bhan, Current Sci. 97, 157–169 (2009).

7. C.J. Mathew, Business Standard (Oct. 2007), p. 16.

8. K. Jayaraman, Nature Biotechnol. 28 (9) 883–884 (2010).

9. E.S. Langer, Gen. Engin. & Biotechnol. News 30 (5) 2010

10. A.S. Rathore, Trends in Biotechnol, 27, (12) 698–705 (2009).

11. A.S. Rathore and I.S. Krull, LCGC North America 28, 598–600 (2010).

12. J.F. Tremblay, Chemical & Engin. News (Aug. 2010), p. 23.

13. A. S. Rathore and H. Winkle H, Nature Biotechnol. 27 (1) (2009) 26–34 (2009).

14. A.S. Rathore, Trends in Biotechnology, 27 (9), 546–553 (2009).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here